Glaukos Bundle
How did Glaukos transform glaucoma care with its go-to-market approach?
Glaukos turned glaucoma surgery into an outpatient, combined‑cataract option with the FDA‑cleared iStent, building surgeon advocacy, strong clinical evidence, and ASCs as distribution channels to drive adoption.
Early strategy used specialty surgical sales, KOL education and procedure pull‑through; current tactics add payer engagement, digital medical education and lifecycle innovation to scale across 25+ countries. See Glaukos Porter's Five Forces Analysis
How Does Glaukos Reach Its Customers?
Sales Channels: Glaukos deploys a multi‑channel commercial strategy combining direct specialty sales, ASC/hospital contracting, international distributor hybrids, payer enablement, digital training, and strategic partnerships to drive adoption of MIGS and corneal therapies.
Direct specialty sales
Core U.S. revenue comes from a >300‑person commercial organization (glaucoma, cornea, market access) in 2024–2025 focused on in‑OR support, coding/reimbursement guidance, and practice development to increase procedure volume.
Hospital / ASC channel
Ambulatory Surgery Centers perform the majority of MIGS in the U.S.; Glaukos contracts with ASC supply chains and GPOs and since 2022 expanded value‑based and capitated bundles to streamline purchasing and reduce point‑of‑care friction.
International distribution
Outside the U.S. Glaukos uses direct subsidiaries in key EU markets and distributor partners in APAC/LatAm; international sales rose to roughly 25–30% of total revenue by 2024, up from below 20% pre‑2020.
Payer & reimbursement enablement
Dedicated market access teams engage CMS and commercial payers to support Category I CPT for MIGS and cross‑linking; 2023–2024 fee stabilization and 2024 coverage gains for iLink improved economics and access.
Digital, training & partnerships
Glaukos leverages HCP portals, virtual proctoring, and e‑learning for surgeon onboarding; digital training now accounts for a meaningful share of initial touchpoints prior to live cases and accelerated post‑COVID adoption.
- Field model emphasizes in‑OR support and practice development to increase combined cataract+MIGS penetration; 60–65% of MIGS are placed during combined cataract cases.
- ASC contracting and GPO deals reduce inventory friction; value‑based/capitated bundles expanded since 2022.
- EU MDR transition post‑2021 prompted stronger direct presence in Germany, UK, Italy; distributor focus retained in Japan and emerging markets.
- Strategic alliances with cataract/IOL ecosystem groups and regional distributors improved share; non‑core low‑margin distribution agreements were ended in 2023–2024 in favor of DTC‑to‑ASC contracting.
See related coverage on commercialization and revenue: Revenue Streams & Business Model of Glaukos
Glaukos SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Marketing Tactics Does Glaukos Use?
Marketing Tactics for Glaukos focus on evidence-led HCP engagement, multichannel professional outreach, digital performance and data-driven personalization to drive adoption of MIGS and corneal products.
Evidence-led HCP marketing
Core messaging anchored in peer‑reviewed trials, podium presence at AAO/ASCRS/ESCRS, and KOL networks. Over 1,000,000 iStent implants globally through 2024–2025 serve as a central proof point supported by RWE on IOP reduction and reduced medication burden.
Account-based professional outreach
Segmentation targets high‑volume cataract surgeons and glaucoma specialists by practice type, therapy mix and payer mix. Tactics include webinars, surgical videos, virtual labs and MSL‑led journal clubs.
CRM and rep deployment
Email nurture and scoring in Salesforce Health Cloud and Veeva (reported by industry sources) guide field rep deployment and account prioritization.
Digital performance
SEO focuses on MIGS, iStent, keratoconus cross‑linking and corneal ectasia; paid search captures referrals. LinkedIn and X engage HCPs; geo‑targeted patient campaigns drive optometrist referrals to corneal specialists via disease‑state education and a find‑a‑doctor directory.
Congress and traditional media
High‑impact booths, live surgical symposia and sponsored education at major meetings remain top ROI channels for surgeon conversion; print in Ophthalmology and Glaucoma Today complements digital.
Data-driven personalization
Procedure propensity models combine CMS claims, practice volumes and permissible EHR integrations to prioritize high‑opportunity accounts. Post‑training cadence and case milestone triggers personalize follow‑ups.
Innovation and measurable outcomes
Post‑2022 marketing innovations include virtual proctoring and remote OR coaching, reducing onboarding time for new MIGS users by approximately 20–30%. Co‑marketing with optometry networks for iLink produced double‑digit increases in first‑diagnosis keratoconus referrals in select 2024 markets; these initiatives align with Glaukos commercial strategy and ophthalmic device marketing best practices. See market context in Target Market of Glaukos.
- Evidence-led HCP marketing anchored by peer‑reviewed data and KOLs
- Account‑based multichannel outreach with Salesforce/Veeva CRM scoring
- SEO/paid search and geo‑targeted patient campaigns for referral capture
- Congress activations and print to convert surgeons
Glaukos PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
How Is Glaukos Positioned in the Market?
Glaukos positions as the pioneer in micro‑invasive and minimally invasive solutions for chronic eye disease, promoting procedure‑based alternatives to lifelong drops and high‑risk surgery with an evidence‑anchored, workflow‑friendly message.
Category leadership
Marketed as the first‑in‑class MIGS leader, the brand emphasizes durable IOP control and medication reduction, with top‑of‑mind awareness for iStent in U.S. surgeon tracking (2023–2024).
Clinical credibility
Tone is authoritative yet accessible, using device imagery, anatomical clarity and outcomes charts to highlight trial data on IOP lowering, corneal stability and medication burden reduction.
Surgeon appeal
Positioning targets surgeons with innovation, an expanding platform (iStent, iAccess/iPRIME, iLink) and consistent perioperative support to drive adoption in combined cataract workflows.
Payer value
Messaging to payers centers on cost offsets from fewer medications and complications, citing real‑world and trial evidence to support reimbursement discussions and health‑economic models.
The brand maintains consistency across HCP, payer and patient touchpoints, with rapid MSL‑led responses to reimbursement or safety narratives and real‑time FAQs to protect perception and adoption.
Differentiation
First‑in‑class MIGS leadership plus pipeline optionality in retina drug delivery and Rho‑kinase therapies distinguishes the brand from rivals in ophthalmic device marketing.
Patient messaging
Communications emphasize safety, faster recovery and reduced medication burden, supporting demand generation and patient education for glaucoma treatment go‑to‑market efforts.
Commercial tactics
Sales and marketing blend direct surgeon engagement, KOL podium presence and digital HCP outreach; brand tracking in 2023–2024 shows iStent leadership in U.S. surgeon awareness.
Support model
Field teams, MSLs and procedural support personnel drive training, adoption and territory management, aligning with Glaukos sales strategy and ophthalmology sales channel strategy.
Reputation metrics
Industry recognition includes frequent podium presentations and surgeon surveys citing 'Most Performed MIGS'; commercial reporting shows consistent uptake in combined cataract cases versus standalone MIGS competitors.
Brand identity
Visuals are clinical and modern, prioritizing device imagery and outcomes charts to support claims about IOP control and medication reduction in marketing collateral.
Key positioning pillars
Brand positioning ties to product, evidence and commercial execution across stakeholders, reinforcing leadership in MIGS and readiness for future ophthalmic innovations.
- First‑in‑class MIGS leadership and platform breadth
- Evidence‑driven outcomes: IOP control, medication reduction, corneal stability
- Surgeon‑centric support and training
- Payer ROI framing via reduced long‑term costs
Related strategic context is summarized in this article: Mission, Vision & Core Values of Glaukos
Glaukos Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Are Glaukos’s Most Notable Campaigns?
Key Campaigns for Glaukos focus on adoption of MIGS and corneal therapies through surgeon training, payer engagement, targeted DTC and digital channels, and evidence scale to drive commercial gains across 2020–2025.
iStent inject W expansion (2021–2023)
Objective: broaden adoption among cataract surgeons by emphasizing ease‑of‑use and dual‑stent efficacy; creative line 'Small device, big impact' highlighted device scale and IOP/meds data; channels included in‑booth wet labs, KOL webinars, targeted email/CRM and surgical video content.
Results and impact
Results: sustained double‑digit MIGS revenue growth through 2023 with share gains in combined cataract procedures and higher pull‑through in ASCs; lesson: procedural simplicity and clinical data drive surgeon conversion and hospital procurement.
iStent infinite launch (2022–2024)
Objective: enter refractory glaucoma segment beyond combined cataract with case‑based storytelling focused on severe glaucoma patients; channels: MSL‑led grand rounds, payer dossiers and focused digital to tertiary centers.
Results and payer lessons
Results: generated a new standalone MIGS revenue stream; coverage expanded across major plans in 2023–2024 improving access; lesson: payer education is critical for standalone indications and reimbursement uptake.
iLink patient‑referral engine (2023–2025)
Objective: increase keratoconus diagnoses and treated patients aged 10–30; creative: 'Ask About Keratoconus' disease‑state awareness targeting parents/teens and optometrist referral CTAs.
Channels and outcomes
Channels: SEO/SEM, meta ads, optometry partnerships, geotargeted landing pages and locator; results: pilot metros saw double‑digit referral increases and 2024 national payer coverage wins reduced out‑of‑pocket friction.
Additional campaigns reinforced scale and training to sustain growth.
Surgeon onboarding at scale (2020–2024)
Creative 'Virtual Proctoring, Real Confidence' used remote OR coaching, VR simulators and on‑demand microlearning; onboarding time fell by approximately 20–30%, preserving training throughput during travel constraints.
Thought leadership & outcomes registry (ongoing)
Campaigns promoted '1,000,000+ implants, and counting' across congress symposia, RWE posters and interactive dashboards; results reinforced brand equity and payer confidence, leveraging scale as a commercial asset.
Commercial and reimbursement emphasis
Focused payer dossiers and real‑world evidence supported coverage expansions in 2023–2024; expanding reimbursement correlated with measurable increases in standalone MIGS procedures and reduced patient cost barriers.
Digital plus physician outreach
Targeted CRM, surgical video libraries and KOL webinars increased surgeon engagement; combined digital and field tactics accelerated funnel conversion for both cataract‑combined and standalone MIGS.
Market expansion metrics
Pilot programs reported double‑digit referral and procedure growth in targeted metros; scaling these campaigns contributed to company MIGS revenue growth rates above market averages through 2023.
Key strategic takeaway
Evidence generation, payer engagement and hybrid training models proved essential to the Glaukos commercial strategy for sustained adoption of MIGS and corneal therapies; see deeper analysis in Growth Strategy of Glaukos.
Glaukos Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of Glaukos Company?
- What is Competitive Landscape of Glaukos Company?
- What is Growth Strategy and Future Prospects of Glaukos Company?
- How Does Glaukos Company Work?
- What are Mission Vision & Core Values of Glaukos Company?
- Who Owns Glaukos Company?
- What is Customer Demographics and Target Market of Glaukos Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.